An oil-in-water nanoemulsion in which the oil globules have a mean size of less than 100 nm and which contains an amphiphilic lipid component containing at least one non-ionic amphiphilic lipid which is liquid at an ambient temperature of less than 45°C The nanoemulsion can be used in the fields of cosmetics and dermopharmaceuticals. The nanoemulsion is stable on storage, can contain significant amounts of oil while retaining good transparency, and can contain heat-sensitive active agents.
|
1. An oil-in-water nanoemulsion comprising water, oil globules having a mean size of less than 100 nm dispersed in an aqueous phase and an amphiphilic lipid component situated at the oil/aqueous phase interface wherein the amphiphilic lipid component comprises at least one non-ionic amphiphilic lipid which is liquid at a temperature of less than 45° C. and wherein the ratio by weight of the amount of oil to the amount of amphiphilic lipid component is from 3 to 10.
2. The nanoemulsion according to
3. The nanoemulsion according to
4. The nanoemulsion according to
5. The nanoemulsion according to
6. The nanoemulsion according to
alkaline salts of dicetyl and dimyristyl phosphate; alkaline salts of cholesterol sulphate; alkaline salts of cholesterol phosphate; salts of amino acids containing fatty groups; sodium salts of phosphatidic acid; phospholipids; and alkylsulphonic derivatives of formula: ##STR2## in which R represents C16 -C22 alkyl radicals, taken as a mixture or separately, and M is an alkali metal.
7. The nanoemulsion according to
8. The nanoemulsion according to
9. The nanoemulsion according to
animal or vegetable oils formed by esters of fatty acids and of polyols vegetable or animal oils of formula R9 COOR10, in which R9 represents the residue of a higher fatty acid containing from 7 to 19 carbon atoms and R10 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms; natural or synthetic essential oils; hydrocarbons; halogenated hydrocarbons; esters of an inorganic acid and of an alcohol; ethers and polyethers; and silicones, as a mixture with at least one of the oils defined above.
10. The nanoemulsion according to
11. The nanoemulsion according to
12. The nanoemulsion according to
13. The nanoemulsion according to
14. The nanoemulsion according to
15. The nanoemulsion according to
16. The nanoemulsion according to
17. The nanoemulsion according to
18. The nanoemulsion according to
19. The nanoemulsion according to
20. The nanoemulsion according to
21. A composition for topical use comprising the nanoemulsion according to
22. A process for the treatment of the skin and/or of the scalp, comprising applying a nanoemulsion according to
23. A process for the preparation of the nanoemulsion as defined in
24. The process according to
|
The present invention relates to an oil-in-water nanoemulsion which is preferably transparent and in which the oil globules have a mean size of less than 100 nm. The invention nanoemulsion further preferably comprises an amphiphilic lipid component based on at least one non-ionic amphiphilic lipid which is liquid at temperatures less than 45°C The invention nanoemulsion is useful for the topical application of, in particular, cosmetics, skin conditioners, and dermopharmaceuticals.
Oil-in-water emulsions are well-known in the field of cosmetics, dermopharmaceuticals, etc., in particular for the preparation of cosmetic products such as lotions, tonics, serums or toilet waters. Transparent microemulsions are also known. Microemulsions are not, strictly speaking, emulsions; these are transparent solutions of micelles, that is to say that the oil present is dissolved therein by virtue of the joint presence of surfactants and of cosurfactants and by virtue, generally, of a high proportion of these surfactants and cosurfactants. The extremely small size of the particles, which is the cause of their transparency, arises from this "solubilization". The disadvantages of these microemulsions, however, are related to their high proportion of surfactants, leading to intolerances and resulting in a sticky feel during application to the skin. Thus, EP-A-572,080 describes microemulsions containing an oil, a fragrance and a mixture of surfactant and of cosurfactant, the proportion of oil and of mixture of surfactant and cosurfactant being between 0.85 and 2.5.
Nanoemulsions comprising oil globules having a mean size of less than 100 nm have already been used in order to obtain transparent compositions having an appearance similar to water and resulting, after application to the skin, in a feel similar to that of a cream or milk. These nanoemulsions, in contrast to microemulsions, are true emulsions where the oil globules are dispersed in an aqueous phase, the surfactants being situated at the oil/aqueous phase interface. The transparency of these emulsions arises from the small size of the oily globules, which small size is obtained by virtue of passing through a high- pressure homogenizer.
Nanoemulsions comprising an amphiphilic lipid phase composed of phosphoglycerides, water and oil are known. These emulsions have the disadvantage of being unstable on storage at conventional storage temperatures, namely between 0° and 45°C They result in yellow compositions and produce a rancid smell which develops after a few days of storage. They are described in EP 406 162.
Nanoemulsions comprising the combination of a long-chain fatty alcohol and/or of a long-chain fatty acid and of a soap type surfactant of a long-chain fatty acid forming a gel, the phase transition temperature of which is greater than 60°C, are also known. These emulsions are prepared at temperatures greater than 70°C which limit the use of heat-sensitive active principles in such compositions. They are described, for example, in EP-A-615,741.
The inventors have unexpectedly discovered new nanoemulsions exhibiting all the advantages of known nanoemulsions without their disadvantages nor the disadvantages of microemulsions. The invention nanoemulsions have oil globules whose mean size is less than 100 nm, and they are stable on storage between 0° and 45°C for at least two months. The nanoemulsions in accordance with the invention are preferably prepared at temperatures between 20° and 450°C and are compatible with heat-sensitive active principles. They can contain significant amounts of oil, while retaining good transparency properties. They can particularly contain significant amounts of fragrance and can improve their persistence. They also promote penetration of the active principles into the surface layers of the skin.
The subject of the present invention is an oil-in-water nanoemulsion having oil globules, the mean size of which is less than 100 nm, and comprising an amphiphilic lipid component, characterized in that the amphiphilic lipid component comprises at least one non-ionic amphiphilic lipid which is liquid at a temperature of less than 45°C and that the ratio by weight of the amount of oil to the amount of amphiphilic lipid component varies from 2 to 10. The invention nanoemulsions are water-containing nanoemulsions.
The amphiphilic non-ionic lipids of the invention are preferably chosen from esters or mixtures of esters of at least one polyol, preferably chosen from polyethylene glycol containing from 1 to 60 ethylene oxide units, sorbitan, glycerol containing from 2 to 30 ethylene oxide units or polyglycerols containing from 2 to 15 glycerol units, with at least one fatty acid containing at least one saturated or unsaturated, linear or branched, C8 -C22 alkyl chain.
Mention may be made, by way of example, of
the isostearate of polyethylene glycol with a molecular weight of 400, sold under the name PEG 400 isostearate by the company Unichema;
diglyceryl isostearate, sold by the company Solvay;
glyceryl laurate containing 2 glycerol units, sold by the company Solvay;
sorbitan oleate, sold under the name Span 80 by the company ICI;
sorbitan isostearate, sold under the name Nikkol SI 10R by the company Nikko;
α-butylglucoside cocoate or α-butylglucoside caprate, marketed by the company ULICE.
The ratio by weight of the amount of oil contained in the emulsion in accordance with the invention to the amount of amphiphilic lipid component (oil/lipid) preferably varies from 3 to 6, but may be as high as 10 and includes 2, 3, 4, 5, 6, 7, 8, and 9 and all values and subranges therebetween.
A specific form of the nanoemulsion in accordance with the invention is characterized in that the amphiphilic lipid component additionally contain one or a number of ionic amphiphilic lipids.
Ionic amphiphilic lipids which may be used in the nanoemulsions of the invention include, and are preferably chosen from the group formed by neutralized anionic lipids, amphoteric ionic lipids or alkylsulphonic derivatives.
They are more preferably chosen from the group formed by:
alkaline salts of dicetyl and dimyristyl phosphate;
alkaline salts of cholesterol sulphate;
alkaline salts of cholesterol phosphate;
amino acids containing fatty groups, such as mono- and disodium acylglutamates;
sodium salts of phosphatidic acid;
phospholipids;
alkylsulphonic derivatives of formula: ##STR1## in which R represents a C16 -C22 alkyl radical, in particular C16 H33 and C18 H37 radicals, taken as a mixture or separately, and M is an alkali metal, such as sodium.
The ionic amphiphilic lipids are present in the nanoemulsions of the invention in concentrations preferably ranging from 2 to 10% by weight and more preferably from 5 to 10% by weight with respect to the total weight of the amphiphilic lipid component.
The nanoemulsions in accordance with the invention contain an amount of oil preferably ranging from 5 to 30% by weight with respect to the total weight of the emulsion.
Oils which can be used in the emulsions of the invention include, and are preferentially chosen from, the group formed by:
animal or vegetable oils formed by esters of fatty acids and of polyols, in particular liquid triglycerides, for example sunflower, maize, soybean, gourd, grape seed, sesame and hazelnut oils, fish oils or caprylic/capric triglyceride, or vegetable or animal oils of formula R9 COOR10, in which R9 represents the residue of a higher fatty acid containing from 7 to 19 carbon atoms and R10 represents a branched hydrocarbon chain containing from 3 to 20 carbon atoms, for example purcellin oil;
natural or synthetic essential oils such as, for example, oils of eucalyptus, of lavandin, of lavender, of vetiver, of Litsea cubeba, of lemon, of santal, of rosemary, of camomile, of savory, of nutmeg, of cinnamon, of hyssop, of caraway, of orange, of geranium, of cade and of bergamot;
hydrocarbons, such as hexadecane and liquid paraffin;
halogenated hydrocarbons, in particular fluorocarbons, such as fluoroamines, for example perfluorotributylamine, fluorinated hydrocarbons, for example perfluorodecahydronaphthalene, fluoroesters and fluoroethers;
esters of an inorganic acid and of an alcohol;
ethers and polyethers;
silicones, as a mixture with at least one of the oils defined above, for example decamethylcyclopentasiloxane or dodecamethylcyclohexasiloxane.
The emulsions in accordance with the present invention can contain additives, in order to improve the transparency of the formulation. These additives are preferably chosen from the group formed by:
lower C1 -C8 alcohols, such as ethanol,
glycols, such as glycerol, propylene glycol, 1,3-butylene glycol, dipropylene glycol or polyethylene glycols containing from 4 to 16 ethylene oxide units and preferably from 8 to 12.
Additives, such as those mentioned above, are present in the emulsions of the invention in concentrations preferably ranging from 5 to 30% by weight with respect to the total weight of the emulsion. The alcohols are preferably used at concentrations ranging from 5 to 20% by weight. The glycols are preferably used as concentrations ranging from 2 to 15% by weight.
In addition, the use of the alcohols as defined above, at concentrations greater than or equal to 15% by weight, make it possible to obtain preservative-free emulsions.
The emulsions of the invention can contain water-soluble or liposoluble active principles (agents) having a cosmetic, dermopharmaceutical, etc. activity. The liposoluble active principles are generally thought to be confined in the oily globules of the emulsion, whereas the water-soluble active principles are thought to be confined in the aqueous phase of the emulsion. Mention may be made, as examples of active principles, of vitamins, such as vitamin E and its derivatives, provitamins, such as panthenol, humectants, sunscreens, etc.
The nanoemulsions in accordance with the invention can also contain adjuvants used for the formulation of the nanoemulsion in the form of a lotion, serum, cream or milk, such as gelling agents, preservatives and fragrances. Mention may be made, among the gelling agents which can be used, of cellulose derivatives, such as hydroxypropyl methyl cellulose, fatty alcohols such as stearyl, cetyl and behenyl alcohols, alga derivatives such as satiagum, natural gums such as gum tragacanth and synthetic polymers such as the mixtures of polycarboxyvinyl acids marketed under the name Carbopol by the company Goodrich and the mixture of Na acrylate/acrylamide copolymers marketed under the name Hostacerin PN 73 by the company Hoechst.
The oil globules of the nanoemulsions of the invention preferably have a mean size ranging from 30 to 75 nm and more preferentially from 40 to 60 nm. They can be as large as less than 100 nm and include 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, and 95 nm and all values and subranges therebetween. The size of the globules makes it possible to promote penetration of the active principles into the surface layers of the skin (carrier effect).
The nanoemulsions according to the invention are preferably colorless or possibly slightly bluish and exhibit a transparency, determined by the transmittance coefficient, measured at a wavelength of 600 nm, preferentially ranging from 30 to 90% and more particularly from 50 to 80%.
The nanoemulsions of the invention can be obtained by a process, characterized in that the aqueous phase and the oily phase are mixed, with vigorous stirring, at an ambient temperature of less than 45°C followed by high-pressure homogenization at a pressure greater than 108 Pa and preferably ranging from 12×107 to 18×107 Pa. Such a process makes it possible to produce, at ambient temperature, nanoemulsions which are compatible with heat-sensitive active compounds and which can contain significant amounts of oils and in particular fragrances which contain fatty substances, without denaturing them.
Further subjects of the invention are a composition for topical use such as a cosmetic or dermopharmaceutical composition, characterized in that it is composed of an emulsion as defined above, and the use of the same on the skin, hair, eyes, face, etc.
A further subject of the invention is the use of the nanoemulsions as defined above as the basis for care and/or make-up products for the skin and/or the face and/or the scalp, such as lotions, serums, milks, creams or toilet waters.
Finally, the invention also relates to a non-therapeutic process for caring for the skin or for the scalp, characterized in that a nanoemulsion as defined above is applied to the skin or to the scalp.
The following examples will make it possible to understand the invention better without, however, having a limiting nature.
For the following Examples 1 to 7, the following procedure is used:
the amphiphilic lipids are homogenized with the oils and the lipophilic active principles and adjuvants at a temperature of 45°C in a first phase A;
the hydrophilic active principles and adjuvants are dissolved at a temperature of 20° to 30°C in a second phase B;
then, the phases A and B are mixed using a turbine homogenizer and then homogenization is carried out using a high-pressure homogenizer of the Soavi-Niro type at a pressure of 1500 bars, over 7 passages, the temperature of the product being maintained below 35°C
In the case of Example 7, the gelling agent is added in a phase C which is mixed with the phases A and B using a turbine homogenizer.
PAC Vitamin-Containing Care WaterFirst Phase
______________________________________ |
PEG-400 isostearate, sold by the company |
4.5% |
Unichema |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Jojoba oil 6% |
Mixture of sunflower, hybrid sunflower, |
6% |
musk rose and blackcurrant seed oils |
Cyclomethicone 7% |
Vitamin E acetate 1% |
Copherol F1300, marketed by Henkel |
0.2% |
Stabilized vitamin A palmitate |
0.1% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Demineralized water 54.7% |
Glycerol 5% |
______________________________________ |
An emulsion is obtained in which the size of the oil globules is 63 nm with a transparency, determined by the transmittance coefficient at 600 nm, equal to 40%.
PAC Care FluidFirst Phase
______________________________________ |
PEG-400 isostearate, sold by the company |
4.5% |
Unichema |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Jojoba oil 5% |
Avocado oil 5% |
Volatile silicone 9% |
Cetyl alcohol 1% |
Vitamin E acetate 1% |
Copherol F1300 0.2% |
Stabilized vitamin A palmitate |
0.1% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Glycerol 5% |
Demineralized water q.s. for |
100% |
______________________________________ |
A thick transparent emulsion is obtained in which the size of the globules is 53 nm and the transparency 60%.
PAC Fluid EyelinerFirst Phase
______________________________________ |
PEG-400 isostearate, sold by the company Unichema |
4.5% |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Jojoba oil 5% |
Light liquid petrolatum 4% |
Avacado oil 4% |
Volatile silicone 6% |
Vitamin E acetate 1% |
Copherol F1300 0.2% |
______________________________________ |
Second Phase
______________________________________ |
Glycerol 5% |
Polyethylene glycol containing 8 ethylene |
10% |
oxide units |
Demineralized water q.s. for |
100% |
______________________________________ |
An opalescent emulsion is obtained in which the size of the globules is 65 nm and the transparency 42%.
PAC Body Care FluidFirst Phase
______________________________________ |
PEG-400 isostearate, sold by the company Unichema |
4.5% |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the company Ajinomoto (ionic |
amphiphilic lipid) |
Light liquid petrolatum 7% |
Avocado oil 7% |
Volatile silicone 6% |
Vitamin E acetate 1% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Glycerol 5% |
Demineralized water q.s. for |
100% |
______________________________________ |
A particularly fluid fluid is obtained in which the size of the globules is of the order of 50 nm and the transparency 60%.
PAC Moisturizing FluidFirst Phase
______________________________________ |
α-Butylglucoside cocoate, marketed by ULICE |
4.5% |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Jojoba oil 5% |
Avocado oil 5% |
Volatile silicone 6% |
Stearyl heptanoate/stearyl caprylate |
2% |
Vitamin E acetate 1% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Glycerol 6% |
Sodium hyaluronate 0.10% |
Demineralized water q.s. for |
100% |
______________________________________ |
A transparent emulsion is obtained in which the size of the globules is 52 nm and the transparency 58%.
PAC Scented FluidFirst Phase
______________________________________ |
PEG-400 isostearate, sold by the company Unichema |
4.5% |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Jojoba oil 4% |
Mixture of sunflower, hybrid sunflower, |
4% |
musk rose and blackcurrant seed oils |
Volatile silicone 6% |
Fragrance 6% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Demineralized water 54.7% |
Glycerol 5% |
Demineralized water q.s. for |
100% |
______________________________________ |
A scented lotion of high persistence is obtained in which the size of the oil globules is 50 nm with a transparency equal to 54%.
PAC Scented BalmFirst Phase
______________________________________ |
α-Butylglucoside cocoate, marketed by ULICE |
4.5% |
Disodium salt of N-stearoyl-L-glutamic acid, |
0.5% |
marketed under the name Acylglutamate |
HS21 by the Company Ajinomoto (ionic |
amphiphilic lipid) |
Mixture of sunflower, hybrid sunflower, |
7% |
musk rose and blackcurrant seed oils |
Light liquid petrolatum 7% |
Volatile silicone 6% |
Fragrance 1.5% |
Vitamin E acetate 0.5% |
Non-denatured absolute ethanol |
15% |
______________________________________ |
Second Phase
______________________________________ |
Glycerol 5% |
Sterile demineralized water q.s. for |
100% |
______________________________________ |
Third Phase
______________________________________ |
Hydroxypropyl cellulose, marketed under |
0.4% |
the name Methocel E 4 M QG by the company Dow Chemical |
Sterile demineralized water 15% |
______________________________________ |
A smooth non-sticky balm is obtained in which the size of the globules is 54 nm and the transparency 53%.
In addition to the specific examples of various components of the invention nanoemulsions given above, those compounds and compositions meeting the functional requirements of the invention components listed in Volumes 1 and 2 of the International Cosmetic Ingredient Dictionary, 6th Ed., 1995, J. A. Wenninger, et al, Eds., published by the Cosmetic, Toiletry and Fragrance Association, incorporated herein by reference, are also to be included. Moreover, each invention component may be a mixture of acceptable compounds or compositions.
This application is based on French Patent Application 95-02268, filed Feb. 27, 1995, incorporated herein by reference.
Simonnet, Jean-Thierry, Legret, Sylvie, Ribier, deceased, Alain
Patent | Priority | Assignee | Title |
10010490, | Dec 04 2012 | Nissan Chemical Industries, Ltd | Cosmetic composition comprising cellulose fibers with small fiber diameter and comparatively small aspect ratio |
10016364, | Jul 18 2005 | University of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
10016451, | May 31 2007 | ANTERIOS, INC | Nucleic acid nanoparticles and uses therefor |
10029013, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free, water-free formable composition and breakable foams and their uses |
10086080, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
10092588, | Jul 29 2009 | JOURNEY MEDICAL CORPORATION | Foamable compositions, breakable foams and their uses |
10117812, | Nov 29 2002 | VYNE THERAPEUTICS INC | Foamable composition combining a polar solvent and a hydrophobic carrier |
10137200, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
10213384, | Apr 28 2009 | JOURNEY MEDICAL CORPORATION | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
10213512, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
10238746, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
10265404, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Compositions, gels and foams with rheology modulators and uses thereof |
10285941, | Dec 01 2006 | Anterios, Inc. | Amphiphilic entity nanoparticles |
10322085, | Oct 25 2002 | VYNE THERAPEUTICS INC | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
10322186, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
10350166, | Jul 29 2009 | VYNE THERAPEUTICS INC | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
10363216, | Apr 28 2009 | JOURNEY MEDICAL CORPORATION | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
10369102, | Aug 07 2008 | VYNE THERAPEUTICS INC | Wax foamable vehicle and pharmaceutical compositions thereof |
10398641, | Sep 08 2016 | JOURNEY MEDICAL CORPORATION | Compositions and methods for treating rosacea and acne |
10463742, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
10517882, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Method for healing of an infected acne lesion without scarring |
10532019, | Dec 01 2005 | University of Massachusetts Lowell | Botulinum nanoemulsions |
10576034, | Dec 01 2005 | University of Massachusetts Lowell | Botulinum nanoemulsions |
10588858, | Apr 28 2009 | JOURNEY MEDICAL CORPORATION | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
10610599, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
10758485, | Dec 01 2006 | Anterios, Inc. | Amphiphilic entity nanoparticles |
10821077, | Oct 25 2002 | VYNE THERAPEUTICS INC | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
10821187, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Compositions, gels and foams with rheology modulators and uses thereof |
10835613, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Compositions, gels and foams with rheology modulators and uses thereof |
10849847, | Sep 08 2016 | JOURNEY MEDICAL CORPORATION | Compositions and methods for treating rosacea and acne |
10905637, | Dec 01 2006 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
10946101, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
10967063, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free, water-free formable composition and breakable foams and their uses |
10980888, | Aug 29 2007 | Agency for Science, Technology and Research | Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use |
11033491, | Mar 11 2005 | VYNE THERAPEUTICS INC | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
11052030, | Sep 29 2015 | Shiseido Company, Ltd. | Method for manufacturing microemulsion-type cosmetic |
11103454, | Aug 07 2007 | VYNE THERAPEUTICS INC | Wax foamable vehicle and pharmaceutical compositions thereof |
11162136, | Apr 15 2020 | ENUMERIX, INC | Systems and methods for generation of emulsions with suitable clarity with applications of use |
11219631, | Jul 29 2009 | JOURNEY MEDICAL CORPORATION | Foamable compositions, breakable foams and their uses |
11242558, | Apr 15 2020 | ENUMERIX, INC | Systems and methods for generation of emulsions with suitable clarity with applications of use |
11311496, | Nov 21 2016 | EIRION THERAPEUTICS, INC | Transdermal delivery of large agents |
11324691, | Sep 08 2016 | JOURNEY MEDICAL CORPORATION | Compositions and methods for treating rosacea and acne |
11414450, | Aug 28 2017 | REVAGENIX, INC | Aminoglycosides and uses thereof |
11433025, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Oil foamable carriers and formulations |
11447817, | Apr 15 2020 | Enumerix, Inc. | Systems and methods for generation of emulsions with suitable clarity with applications of use |
11542546, | Apr 15 2020 | Enumerix, Inc. | Systems and methods for generation of emulsions with suitable clarity with applications of use |
11673907, | Apr 03 2018 | REVAGENIX, INC | Modular synthesis of aminoglycosides |
11814619, | Jun 04 2021 | ENUMERIX, INC | Compositions, methods, and systems for single cell barcoding and sequencing |
11834714, | Dec 20 2021 | ENUMERIX, INC | Detection and digital quantitation of multiple targets |
12129274, | Apr 03 2018 | REVAGENIX, INC. | Modular synthesis of aminoglycosides |
12138311, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
6039936, | Nov 15 1996 | L Oreal | Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof |
6071524, | Nov 10 1994 | L'Oreal | Oily phase in aqueous phase dispersion stabilized by cubic gel particles and method of making |
6274150, | Dec 23 1998 | L Oreal | Nanoemulsion based on phosphoric acid fatty acid esters and its uses in the cosmetics, dermatological, pharmaceutical, and/or ophthalmological fields |
6335022, | Dec 17 1998 | L Oreal | Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields |
6461625, | Feb 02 1999 | L Oreal | Nanoemulsion based on alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its uses in the cosmetics, dermatological, opthalmological and/or pharmaceutical fields |
6464990, | Jan 05 1999 | L'Oreal | Nanoemulsion based on ethylene oxide and propylene oxide block copolymers and its uses in the cosmetics, dermatological and/or ophthalmological fields |
6468551, | Oct 10 1996 | Beiersdorf AG | Cosmetic or dermatological preparations based on emulsifiers which are free from ethylene oxide and propylene oxide, for the preparation of microemulsion gels |
6488780, | Nov 15 1996 | L'Oreal S.A. | Detergent cosmetic compositions and use thereof |
6491902, | Jan 29 2001 | Salvona LLC | Controlled delivery system for hair care products |
6537561, | Feb 27 1997 | Nippon Shinyaku Co., Ltd. | Fat emulsion for oral administration |
6541029, | Aug 31 1998 | Nipro Corporation | Nutrient infusion preparation |
6559183, | Nov 12 1998 | BIOFRONTERA BIOSCIENCE GMBH | Nano-emulsion of 5-aminolevulinic acid |
6689371, | Dec 14 1998 | L Oreal | Nanoemulsion based on sugar fatty esters or on sugar fatty ethers and its uses in the cosmetics, dermatological and/or ophthalmological fields |
6773627, | Jun 29 2000 | Children's Hospital Research Foundation | Cubic liquid crystalline compositions and methods for their preparation |
6774101, | Oct 20 2000 | Firmenich SA | Alcohol-free perfuming composition |
6979440, | Jan 29 2001 | SALVONA L L C | Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric |
6998426, | Jul 13 2000 | L Oreal | Nanoemulsion containing nonionic polymers, and its uses |
7153516, | Jul 02 2001 | Color Access, Inc. | Ringing nanogel compositions |
7300912, | Aug 10 2005 | Foaming cleansing preparation and system comprising coated acid and base particles | |
7763663, | Dec 19 2001 | MASSACHUSETTS, UNIVERSITY OF | Polysaccharide-containing block copolymer particles and uses thereof |
8114385, | Aug 04 2003 | VYNE THERAPEUTICS INC | Oleaginous pharmaceutical and cosmetic foam |
8114389, | Jan 21 2000 | L'Oreal S.A. | Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one nonionic polymer, and uses thereof |
8119106, | Apr 28 2003 | VYNE THERAPEUTICS INC | Foamable iodine compositions |
8119109, | Oct 25 2002 | VYNE THERAPEUTICS INC | Foamable compositions, kits and methods for hyperhidrosis |
8119150, | Oct 25 2002 | VYNE THERAPEUTICS INC | Non-flammable insecticide composition and uses thereof |
8318181, | Dec 01 2005 | University of Massachusetts Lowell | Botulinum nanoemulsions |
8343945, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
8362091, | Aug 04 2003 | VYNE THERAPEUTICS INC | Foamable vehicle and pharmaceutical compositions thereof |
8435498, | Oct 24 2002 | VYNE THERAPEUTICS INC | Penetrating pharmaceutical foam |
8486374, | Apr 28 2004 | VYNE THERAPEUTICS INC | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
8486375, | Apr 28 2003 | VYNE THERAPEUTICS INC | Foamable compositions |
8486376, | Oct 25 2002 | VYNE THERAPEUTICS INC | Moisturizing foam containing lanolin |
8512718, | Jul 03 2000 | VYNE THERAPEUTICS INC | Pharmaceutical composition for topical application |
8513311, | Nov 22 2005 | Nestec S A | Oil-in-water emulsion and its use for the delivery of functionality |
8518376, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Oil-based foamable carriers and formulations |
8518378, | Aug 04 2003 | VYNE THERAPEUTICS INC | Oleaginous pharmaceutical and cosmetic foam |
8618081, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Compositions, gels and foams with rheology modulators and uses thereof |
8636982, | Aug 07 2007 | VYNE THERAPEUTICS INC | Wax foamable vehicle and pharmaceutical compositions thereof |
8703105, | Aug 04 2003 | VYNE THERAPEUTICS INC | Oleaginous pharmaceutical and cosmetic foam |
8709385, | Jan 14 2008 | VYNE THERAPEUTICS INC | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
8722021, | Oct 25 2002 | VYNE THERAPEUTICS INC | Foamable carriers |
8722131, | Sep 07 2010 | DSM NUTRITIONAL PRODUCTS AG | Comestible emulsions |
8741265, | Oct 25 2002 | VYNE THERAPEUTICS INC | Penetrating pharmaceutical foam |
8760906, | Nov 24 2009 | OVONYX MEMORY TECHNOLOGY, LLC | Techniques for reducing disturbance in a semiconductor memory device |
8795635, | Nov 14 2006 | VYNE THERAPEUTICS INC | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
8795693, | Aug 04 2003 | VYNE THERAPEUTICS INC | Compositions with modulating agents |
8834903, | Dec 14 1998 | L'Oreal | Nanoemulsion based on sugar fatty esters or on sugar fatty ethers and its uses in the cosmetics, dermatological and/or ophthalmological fields |
8840869, | Oct 25 2002 | VYNE THERAPEUTICS INC | Body cavity foams |
8865139, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
8871184, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
8900553, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Oil and liquid silicone foamable carriers and formulations |
8900554, | Nov 29 2002 | VYNE THERAPEUTICS INC | Foamable composition and uses thereof |
8920786, | Jun 19 2007 | Cognis IP Management GmbH | Shampoo composition having improved care properties |
8945516, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
8992896, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
8999893, | Feb 04 2008 | Dow Agrosciences LLC | Stabilized oil-in-water emulsions including meptyl dinocap |
9050253, | Aug 04 2003 | VYNE THERAPEUTICS INC | Oleaginous pharmaceutical and cosmetic foam |
9072667, | Jul 29 2009 | VYNE THERAPEUTICS INC | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
9101662, | Aug 04 2003 | VYNE THERAPEUTICS INC | Compositions with modulating agents |
9161916, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
9161921, | Dec 28 2010 | Colloidal carrier system with penetration properties for encapsulating lipophilic active agents and oils for topical use | |
9167813, | Jul 29 2009 | VYNE THERAPEUTICS INC | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
9185905, | Mar 07 2008 | CORTEVA AGRISCIENCE LLC | Stabilized oil-in-water emulsions including agriculturally active ingredients |
9211259, | Nov 29 2002 | VYNE THERAPEUTICS INC | Antibiotic kit and composition and uses thereof |
9265725, | Oct 25 2002 | VYNE THERAPEUTICS INC | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
9320705, | Oct 25 2002 | VYNE THERAPEUTICS INC | Sensation modifying topical composition foam |
9345651, | Jan 24 2011 | Chanel Parfums Beaute | Oil-in-water emulsion composition and method for producing the same |
9426982, | Feb 04 2008 | Dow Agrosciences LLC | Stabilized oil-in-water emulsions including agriculturally active ingredients |
9439857, | Nov 30 2007 | VYNE THERAPEUTICS INC | Foam containing benzoyl peroxide |
9486408, | Dec 01 2005 | University of Massachusetts Lowell | Botulinum nanoemulsions |
9486409, | Dec 01 2006 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
9492412, | Oct 25 2002 | VYNE THERAPEUTICS INC | Penetrating pharmaceutical foam |
9539208, | Oct 25 2002 | VYNE THERAPEUTICS INC | Foam prepared from nanoemulsions and uses |
9549898, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Oil and liquid silicone foamable carriers and formulations |
9572775, | Jul 29 2009 | VYNE THERAPEUTICS INC | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
9622947, | Oct 25 2002 | VYNE THERAPEUTICS INC | Foamable composition combining a polar solvent and a hydrophobic carrier |
9636405, | Aug 04 2003 | VYNE THERAPEUTICS INC | Foamable vehicle and pharmaceutical compositions thereof |
9649275, | Nov 28 2007 | Commonwealth Scientific and Industrial Research Organisation | Nanoemulsions |
9662298, | Aug 07 2008 | VYNE THERAPEUTICS INC | Wax foamable vehicle and pharmaceutical compositions thereof |
9668972, | Oct 25 2002 | VYNE THERAPEUTICS INC | Nonsteroidal immunomodulating kit and composition and uses thereof |
9675700, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Topical tetracycline compositions |
9682021, | Nov 14 2006 | VYNE THERAPEUTICS INC | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
9713643, | Oct 25 2002 | VYNE THERAPEUTICS INC | Foamable carriers |
9724299, | Dec 01 2006 | Anterios, Inc. | Amphiphilic entity nanoparticles |
9795564, | Dec 07 2007 | JOURNEY MEDICAL CORPORATION | Oil-based foamable carriers and formulations |
9812179, | Nov 24 2009 | OVONYX MEMORY TECHNOLOGY, LLC | Techniques for reducing disturbance in a semiconductor memory device |
9849142, | Oct 02 2009 | JOURNEY MEDICAL CORPORATION | Methods for accelerated return of skin integrity and for the treatment of impetigo |
9884017, | Apr 28 2009 | JOURNEY MEDICAL CORPORATION | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
ER1474, | |||
ER8650, |
Patent | Priority | Assignee | Title |
EP334777A1, | |||
EP490053A1, | |||
EP516508A1, | |||
EP572080A1, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 26 1996 | L'Oreal | (assignment on the face of the patent) | / | |||
Jun 11 1996 | SIMONNET, JEAN-THIERRY | L Oreal | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008045 | /0503 | |
Jun 11 1996 | LEGRET, SYLVIE | L Oreal | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008045 | /0503 | |
Jun 12 1996 | RIBIER, ALAIN | L Oreal | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008045 | /0503 |
Date | Maintenance Fee Events |
Feb 10 1999 | ASPN: Payor Number Assigned. |
Sep 27 2001 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
Oct 28 2005 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Oct 21 2009 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
May 19 2001 | 4 years fee payment window open |
Nov 19 2001 | 6 months grace period start (w surcharge) |
May 19 2002 | patent expiry (for year 4) |
May 19 2004 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 19 2005 | 8 years fee payment window open |
Nov 19 2005 | 6 months grace period start (w surcharge) |
May 19 2006 | patent expiry (for year 8) |
May 19 2008 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 19 2009 | 12 years fee payment window open |
Nov 19 2009 | 6 months grace period start (w surcharge) |
May 19 2010 | patent expiry (for year 12) |
May 19 2012 | 2 years to revive unintentionally abandoned end. (for year 12) |